Janney Montgomery Scott Downgrades Cerulean Pharma (CERU) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Leerink Partners Downgrades Cerulean Pharma (CERU) to Market Perform
August 18, 2016 7:29 AM EDTLeerink Partners downgraded Cerulean Pharma (NASDAQ: CERU) from Outperform to Market Perform with a price target of $1.50 (from $8.00). The change follows disappointed CRLX-101 trial results.
"We are downgrading CERU to MP following the failure of lead product candidate CRLX-101 (camptothecin nanoparticle-drug conjugate/NDC) in a... More
Cerulean Pharma (CERU) Says CRLX101 Combo Phase 2 Missed Primary Endpoint
August 17, 2016 4:02 PM EDTCerulean Pharma Inc. (Nasdaq: CERU) announced top-line results from the Companys Phase 2, randomized, multi-center clinical trial of its lead candidate, CRLX101, in combination with Avastin® (bevacizumab) in the treatment of patients with advanced renal cell carcinoma (RCC).
The trial was conducted at 43 sites in the US and South Korea, and enrolled 115 patients with RCC who progressed... More
Cerulean Pharma (CERU) halted with news pending
August 17, 2016 4:00 PM EDTCerulean Pharma (NASDAQ: CERU) halted with news pending.
... More